<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532974</url>
  </required_header>
  <id_info>
    <org_study_id>EP-HIV-1090</org_study_id>
    <nct_id>NCT00532974</nct_id>
  </id_info>
  <brief_title>A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)</brief_title>
  <acronym>EP1090</acronym>
  <official_title>A Phase 1 Safety and Immunogenicity Study of the Pharmexa-Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090) Administered Using a Biojector 2000 Needle Free Immunization Device in HIV-1 Infected Individuals Receiving Potent Combination Antiretroviral Therapy (ART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmexa A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmexa-Epimmune</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Epimmune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of a Bioject 2000 needle free injection device (NFID) and a compressed immunization
      schedule will be safely tolerated and will augment the immunogenicity of the HIV-1 CTL
      epitope DNA vaccine (EP1090) in HIV-1 infected individuals receiving potent combination
      antiretroviral therapy (ART) and who have undetectable levels of viral replication in plasma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">April 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Immunogenicity: defined as the effect of the vaccine on peripheral blood CD8 CTL responses, CD4 T cell counts, plasma HIV-1 RNA levels and clinical signs and symptoms.</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EP1090</intervention_name>
    <description>Low dose</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EP1090</intervention_name>
    <description>High dose</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 Infection

          -  CD4 Tcell count &gt;350

          -  HIV-1 RNA levels to &lt;400 copies

          -  Negative HbsAg and anti-HCV antibody

        Exclusion Criteria:

          -  Recent receipt of experimental HIV-1 vaccines

          -  Recent use of immunomodulatory agents

          -  Hypersensitivity or serious reactions to study vaccine components

          -  Active opportunistic infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AIDS Research Alliance</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <last_update_submitted>December 19, 2007</last_update_submitted>
  <last_update_submitted_qc>December 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2007</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>Vaccines</keyword>
  <keyword>HIV Vaccines</keyword>
  <keyword>Peptide</keyword>
  <keyword>Peptide Vaccines</keyword>
  <keyword>HIV 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

